scholarly journals A Case of Thyroid Hemiagenesis Associated With Graves’ Disease and Follicular Neoplasm

2015 ◽  
Vol 6 (8) ◽  
pp. 385-387
Author(s):  
Bu Kyung Kim ◽  
Ju Won Lee ◽  
Min Jung Jung ◽  
Eun Mi Lee ◽  
So Young Ock ◽  
...  
Keyword(s):  
Follicular Neoplasm ◽  
Graves Disease ◽  
Thyroid Hemiagenesis

A Singular Case of Graves’ Disease in Congenital Thyroid Hemiagenesis

2005 ◽  
Vol 63 (3) ◽  
pp. 107-110 ◽  
Author(s):  
Marina Baldini ◽  
Alessandra Orsatti ◽  
Luigi Cantalamessa
Keyword(s):  
Graves Disease ◽  
Singular Case ◽  
Thyroid Hemiagenesis

scholarly journals Graves′ disease with thyroid hemiagenesis: A rare abnormality with rarer presentation

2014 ◽  
Vol 29 (2) ◽  
pp. 124 ◽  
Author(s):  
Rajeev Philip ◽  
Athulya Ashokan ◽  
Renjit Philip ◽  
Charamelsankaran Keshavan
Keyword(s):  
Graves Disease ◽  
Thyroid Hemiagenesis

scholarly journals MON-547 Post-Surgically Discovered Differentiated Thyroid Microcarcinomas Are More Commonly Found in Patients eith Chronic Lymphocytic Thyroiditis Compared to Those with Multinodular Goiter or Graves' Disease

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Rodis Paparodis ◽  
Karvounis Evaggelos ◽  
Dimitra Bantouna ◽  
Charilaos Chourpiliadis ◽  
Hourpiliadi Hara ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Surgery ◽  
Multinodular Goiter ◽  
Tertiary Care ◽  
Surgical Pathology ◽  
Follicular Neoplasm ◽  
Graves Disease ◽  
Tumor Diameter ◽  
Chronic Lymphocytic Thyroiditis ◽  
Lymphocytic Thyroiditis

Abstract Introduction: Incidental finding of differentiated thyroid microcarcinomas (DTMc) in patients with thyroid nodules, undergoing thyroid surgery for benign indications, have become increasingly common. Even though carcinogenesis might relate to the background disease of the gland, the incidence of DTMc in the setting of various thyroid disorders remains unclear. We designed the present study to address this question. Methods/ Subjects: We reviewed the data from two prospectively collected databases of patients undergoing thyroid surgery in two high-volume tertiary care referral centers, one in the USA (A) and the other one in Greece (B) over 14 consecutive years. We collected data on the preoperative surgical indication, FNA cytology and surgical pathology. We excluded subjects operated for thyroid cancer or indications at high risk for malignancy (FNA suspicious for thyroid cancer, follicular neoplasm, suspicious for follicular neoplasm, FLUS/AUS, cellular specimen or sonographic features of malignancy), and those with post-surgical pathology consistent with PTC >9mm in largest diameter. We split our subjects based on pathology data in those with chronic lymphocytic thyroiditis (CLT), Graves disease (GR) or multinodular goiter (MNG). Incidence of DTMc or features of tumor aggressiveness were compared among groups, using Fischer’ s exact test and odds ratios (OR) were calculated. Categorical values were compared with Kruskal Wallis test. P values <0.05 were deemed significant. Results: We reviewed 6096 cases of thyroid surgery (A:2711, B:3385). We included 3909 subjects. Overall 609 (15.6%) DTMc were identified [A:256/2003 (12.8%), B:353/1906(18.5%) OR 0.79, p<0.0001]. CLT was present in 626 subjects; where DTMc was present in 155 (24.8%) [A:83/410 (20.2%), B: 72/216 (33.3%), OR 0.51 p<0.001]. GR was present in 377 subjects; where DTMc was present in 39 (10.3%) subjects [A:14/209 (6.7%) B: 25/168 (14.9%) OR 0.41, p=0.01]. MNG was present in 1964 subjects; where DTMc was present in 314 (15.9%) subjects [A: 58/686 (8.5%), B:256/1278 (20.0%)]. The incidence of DTMc was significantly higher in CLT compared to MNG (OR 1.73) or GR (OR 2.85) (p<0.001 for both) and in MNG compared to GR (OR 1.64, p=0.0064). Maximal tumor diameter was not significantly different among groups (CLT 0.46cm, MNG 0.44cm, GR 0.44cm, p=0.56). Conclusions: Incidentally discovered differentiated thyroid microcarcinomas are more commonly identified in surgical specimens from subjects with chronic lymphocytic thyroiditis as compared to patients with multinodular goiter, while patients with Graves' disease present with a much smaller incidence compared to both groups. This data supports previously published findings that euthyroid Hashimoto thyroiditis could allow for carcinogenesis, while Graves disease could have a protective role.

scholarly journals A UK reported case of Graves’ disease with thyroid hemiagenesis

2019 ◽  
Vol 12 (8) ◽  
pp. e228094 ◽  
Author(s):  
Jack Faulkner ◽  
Kiran Varadharajan ◽  
Natasha Choudhury
Keyword(s):  
Rare Case ◽  
Postoperative Outcome ◽  
Graves Disease ◽  
Thyroid Lobe ◽  
Thyroid Hemiagenesis ◽  
The Uk ◽  
Left Thyroid Lobe

We present a rare case of a 31-year-old patient with Graves’ disease with agenesis of the left thyroid lobe. The patient was managed with a right hemithyroidectomy and isthmusectomy as definitively treatment of Graves’ disease. The patient had an uneventful postoperative outcome and the histology was benign and consistent with Graves’ disease. This is a rare case in the literature of Graves’ disease with unilateral thyroid agenesis, and to our knowledge is the first reported case from the UK.

Toxic Graves' Disease with Thyroid Hemiagenesis: Diagnosis Using Thyroid-Stimulating Immunoglobulin Measurements

Thyroid ◽  
1992 ◽  
Vol 2 (2) ◽  
pp. 133-135 ◽  
Author(s):  
CARMELA SHECHNER ◽  
ZAKI KRAIEM ◽  
ELIMELECH ZUCKERMAN ◽  
GABRIEL DICKSTEIN
Keyword(s):  
Graves Disease ◽  
Thyroid Hemiagenesis

scholarly journals Thyroid Hemiagenesis with Graves' Disease, Graves' Ophthalmopathy and Multinodular Goiter

2009 ◽  
Vol 48 (12) ◽  
pp. 1047-1049 ◽  
Author(s):  
Mehtap Cakir ◽  
Sait Gonen ◽  
Oguz Dikbas ◽  
Banu Ozturk
Keyword(s):  
Multinodular Goiter ◽  
Graves Disease ◽  
Thyroid Hemiagenesis ◽  
Graves Ophthalmopathy

scholarly journals Title: Case of Hyperthyroidism in a Patient on Anti-PD-1 (Programmed Cell Death Receptor-1 Blocking Antibody) Therapy Caused by Destructive Thyroiditis Followed by Graves’ Disease

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A968-A969
Author(s):  
Chandrika Reddy ◽  
Mohsen Zena
Keyword(s):  
Cervical Cancer ◽  
Thyroid Dysfunction ◽  
Follicular Neoplasm ◽  
Graves Disease ◽  
Contrast Study ◽  
Advanced Cervical Cancer ◽  
Normal Range ◽  
Free T4 ◽  
Iodinated Contrast ◽  
Risk Of Malignancy

Abstract Introduction: Immune checkpoint inhibitor (ICI) related thyroid dysfunction such as destructive thyroiditis and hypothyroidism can occur with Anti-PD-1 therapy. Graves’ disease (GD) however is considered rare. We report a case of isolated hyperthyroidism in a patient on Pembrolizumab, Anti-PD-1 presenting initially as destructive thyroiditis and later transitioned to GD. Case: 57 y.o lady was diagnosed with squamous cell carcinoma of cervix, stage 4 in 2016. She was noted to have asymptomatic goiter in 1997. PET scan in 02/2017 showed hypermetabolic activity in the right lobe nodule of 5.6 cm with maximum SUV of 9.8. Baseline TSH was in normal range in 04/2017. US guided fine needle biopsy of the nodule resulted as follicular neoplasm with 15-30%, risk of malignancy. Molecular test showed 40% risk of malignancy. Lobectomy was deferred. Pembrolizumab was initiated for advanced cervical cancer in 07/2018. Repeat PET in 10/2018 showed resolution of metastasis and right thyroid mass was stable. TSH remained in euthyroid range for 4 months until 11/ 2018. In 01/2019, her TSH was low and became undetectable in 03/2019 with high free T4 and total T3. She developed symptoms of hyperthyroidism. TSI was positive and TSHR Ab was negative. RAIU was low. No iodinated contrast study done prior to I123 scan. In 05/2019 to 08/2019, free T4 and total T3 was normal range with detectable but low TSH consistent with transient resolving thyroiditis. In 10/2019, thyroid hormones significantly increased with recurrence of hyperthyroidism. Both TSI and TSHR Ab were elevated confirming diagnosis of GD. Due to overt thyrotoxicosis, Methimazole (MMI) was initiated in 10/2019. She was briefly lost to follow up and stopped MMI. RAIU scan in 12 /2019 showed increased uptake consistent with GD. MMI was resumed in 04/2020. 06/2020 - 09/2020, MMI dose was titrated to achieve euthyroid state. In 09/25/2020, hypothyroidism was noted which improved with MMI dose reduction. Anti- TPO and Anti-Tg were negative. Pembrolizumab was stopped in 07/2020 due to dilated cardiomyopathy. She completed 2-year course of Pembrolizumab with advanced cervical cancer showing excellent response. Discussion: Observed thyroid dysfunction with ICI, is transient destructive thyroiditis followed by hypothyroidism, which can be permanent. Our patient had an initial low RAIU indicating destructive thyroiditis along with, mildly elevated TSI suggestive of superimposed autoimmune process. The elevated TSI predisposed to later occurrence of GD likely precipitated by Pembrolizumab. MMI provided therapeutic benefit. Conclusion: Less than 10 cases of GD with ICI and 5 cases of GD with Anti-PD- 1 have been reported. Our patient is a second case of persistent hyperthyroidism due to GD induced by Pembrolizumab. GD should be considered if hyperthyroidism persists or recurs in patients on ICI with destructive thyroiditis, which is mostly transient.

scholarly journals CT and MR imagings of single thyroid lobe (thyroid hemiagenesis) with Graves' disease.

1991 ◽  
Vol 67 (789) ◽  
pp. 701-701 ◽  
Author(s):  
H. Sasaki ◽  
T. Futata ◽  
H. Ninomiya ◽  
Y. Higashi ◽  
M. Okumura
Keyword(s):  
Graves Disease ◽  
Thyroid Lobe ◽  
Thyroid Hemiagenesis
Sign in / Sign up

Export Citation Format

Share Document